Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) | MicrobiomeTrials← Back to trialsNCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-09-15Est. Completion: 2028-01-01
Enrollment target: 15 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
COVID-19
In many national Coronavirus Disease 2019 (COVID-19) response plans, including in Kenya and Cameroon, antigen detection …
Yaoundé, CameroonCompleted Oct 31, 2022
Respiratory Distress Syndrome, Adult
Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical …
Los Angeles, United StatesEst. completion Jun 30, 2026